GLP-1 'alternatives' on TikTok: what the evidence actually says

What did @_miss_monroe_ actually say?

She said she found a supplement that works as a "GLP-1 alternative" and that after three days, she "can't even finish" her favorite foods, including a smoothie bowl and a sandwich. She described the appetite suppression as so strong she had to force herself to eat, and noted she only had a protein shake by 2pm. She acknowledged she's not a doctor and recommended consulting one, and framed this as a supplement pick for people who can't access or afford GLP-1 medications.

To be clear about what she didn't say: she never named the supplement on screen, directed viewers to her storefront instead. That matters for evaluating the claim, because "GLP-1 alternative" is a marketing category, not a regulatory one. Dozens of products use that label. Without knowing the ingredients, most of what follows applies to the general category.

Does the science back this up?

No supplement currently on the market replicates how GLP-1 receptor agonists work. That's not a minor distinction. The appetite suppression from semaglutide or tirzepatide comes from directly activating GLP-1 receptors in the brain and gut. No over-the-counter ingredient does that.

What some supplements do contain are ingredients with modest evidence for appetite or satiety effects. Glucomannan, a soluble fiber, was shown in a 2005 Cochrane-adjacent review (Pittler and Ernst, 2005, American Journal of Clinical Nutrition) to produce small but real reductions in body weight. Berberine gets compared to GLP-1 drugs online, but a 2023 meta-analysis (Yin et al., 2023, Frontiers in Pharmacology) found its weight loss effects are modest and mechanisms are indirect, primarily through AMPK activation and gut microbiome changes. 5-HTP may reduce caloric intake in some studies, but effect sizes are small. None of these approaches the 10-15% body weight loss seen in semaglutide trials (Wilding et al., 2021, New England Journal of Medicine).

Three days is also nowhere near enough time to evaluate anything. That timeline is more consistent with placebo response or a coincidental change in appetite, not a documented pharmacological effect.

What did they get wrong (or right)?

Wrong: Calling anything a "GLP-1 alternative" that isn't a GLP-1 receptor agonist is misleading by definition. The framing implies similar mechanisms and similar results. The evidence does not support that for any supplement category. Her description of not finishing a sandwich on day one as proof of efficacy is anecdotal reasoning from a sample size of one, over 72 hours.

She also doesn't name the product, which makes the claim unverifiable and puts viewers in the position of hunting through her storefront. That's a conflict of interest worth naming.

What she got right: she did say "I'm not a doctor, please consult whoever needs to consult." That disclaimer is minimal but it's there. She also correctly identified that GLP-1 medications are expensive and inaccessible for many people, which is a real and documented barrier. A 2023 analysis in Health Affairs (Dusetzina et al., 2023) found out-of-pocket costs for semaglutide can exceed $900 per month without insurance coverage. The frustration driving people toward supplements is legitimate. The supplements themselves are another matter.

What should you actually know?

The supplement industry is not regulated the same way pharmaceuticals are. The FDA does not approve dietary supplements for safety or efficacy before they go to market. That means a product can be labeled a "GLP-1 alternative" and sold legally, even if no clinical trial has tested it in humans for that purpose.

If you are genuinely interested in GLP-1 medications and can't afford them, there are legitimate pathways worth exploring. Manufacturer patient assistance programs exist for Wegovy and Ozempic. Telehealth platforms operating under physician oversight can provide access to FDA-approved compounded semaglutide during shortage periods, though the FDA shortage designation for semaglutide officially ended in 2025, which affects compounding availability. A licensed provider can walk you through what's actually available and appropriate for your situation.

The deeper issue here is that "it worked for me for three days" is one of the weakest forms of evidence in nutrition and pharmacology. Appetite naturally fluctuates. Novelty affects eating behavior. Placebo effects are real and well-documented, including in weight loss contexts (Crum and Langer, 2007, Psychological Science). None of that means the supplement caused anything.

Bottom line

@_miss_monroe_ found something that, for her, seemed to reduce appetite over three days. That experience is real to her. But "I couldn't finish my smoothie bowl" is not evidence that a supplement mimics a drug class with 15+ years of clinical trial data behind it. The GLP-1 alternative label is a marketing claim, not a scientific one. If reducing food intake and managing weight is a genuine health goal, that conversation belongs with a clinician, not a storefront link.